A Phase II Exploratory Study of IMATINIB High Dose (800mg/gg) in the Treatment of Newly Diagnosed Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2017
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 01 Aug 2017 Results of long term outcomes (n=559) of 3 studies (CML021, CML022, CML023) published in the American Journal of Hematology.
- 08 Dec 2015 Long term analysis of 3 trials (n=559) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 10 Dec 2013 Pooled analysis of long-term outcomes presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.